Il Dong Pharm Q1 2026: Net Profit Turnaround, Dividend, Credit Upgrade, Pipeline Progress
Consolidated Q1 2026: Revenue KRW 141.9B, operating profit KRW 9.2B (OPM 6.5%), net profit KRW 7.4B, turning from net loss in prior year.
10th AGM approved cash dividend of KRW 200 per share (year-end); policy to maintain minimum KRW 200 for 2026 year-end dividend.
Credit rating upgraded to A3+ (Korea Ratings, Dec 2025); adjusted debt ratio improved to 20.44% (from 22.40%).
COVID-19 treatment Xocova: FDA review for post-exposure prophylaxis (PDUFA June 16, 2026), Japan approved prophylaxis indication (Mar 2026), preparing re-filing in Korea.
P-CAB acid reflux drug ID120040002 (Padoprazan): Phase 3 ongoing (started Oct 2025), aiming to complete within 2026, co-development with Daewon Pharm.
In March 2026, signed exclusive distribution deal with Viatris Korea for urology; in April, decided to merge with subsidiary Yunovia (effective June 16, 2026).